#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial
NEW ORLEANS — ALX Oncology said it’s getting some promising, if very early, signals from a small trial that could give its CD47 drug new life.
The biotech released data from a Phase I dose-escalation study Monday, showing that three patients with newly diagnosed acute myeloid leukemia (AML) all saw a positive response to a combination therapy that included evorpacept, ALX’s CD47-targeting candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.